Top

03-25-2016 | Retinopathy | Review | Article

The Role of Systemic Risk Factors in Diabetic Retinopathy

Journal: Current Ophthalmology Reports

Authors: Elizabeth Atchison, Andrew Barkmeier

Abstract

Diabetic retinopathy is an increasingly common medical issue in the United States. The risk of developing the disease or having the disease progress is caused by many systemic health factors. This article examines the existing literature on the links between glycemic control, arterial hypertension, high cholesterol and hyperlipidemia, obesity, inflammatory markers, sleep-disordered breathing, and exercise with risk of diabetic retinopathy development and prevention. The literature shows benefit for good glycemic and blood pressure control. The effects of cholesterol, and lipid control, inflammatory markers, sleep-disordered breathing, obesity, and exercise are less well established.

Economic costs of diabetes in the. U.S. in 2012. Diabetes Care. 2013;36(4):1033–46.CrossRef

Boyle JP, Thompson TJ, Gregg EW, et al. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr. 2010;8:29.CrossRefPubMedPubMedCentral

Saaddine JB, Honeycutt AA, Narayan KM, et al. Projection of diabetic retinopathy and other major eye diseases among people with diabetes mellitus: United States, 2005–2050. Arch Ophthalmol. 2008;126(12):1740–7.CrossRefPubMed

Third Report of the National Cholesterol Education Program. (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–421.

Costa LA, Canani LH, Lisboa HR, et al. Aggregation of features of the metabolic syndrome is associated with increased prevalence of chronic complications in Type 2 diabetes. Diabet Med. 2004;21(3):252–5.CrossRefPubMed

The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–86.CrossRef

Chew EY, Ambrosius WT, Davis MD, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363(3):233–44.CrossRefPubMed

Hemmingsen B, Lund SS, Gluud C, et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2013;11:008143.

Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes. 1995;44(8):968–83.CrossRef

10.

Diabetes Control and Complications Trial Research Group. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Ophthalmology. 1995;102(4):647–61.CrossRef

11.

Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med. 1993;329(5):304–9.CrossRefPubMed

12.

• Lachin JM, White NH, Hainsworth DP, et al. Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT/EDIC. Diabetes 2015;64(2):631–42. This is a continuation of the landmark Diabetes Control and Complications Trial, which established the lower rate of microvascular complications for intensive glucose control in type 1 diabetes. Previous follow up studies showed the effect of “metabolic memory” where the effects of the intensive glucose management persisted through 10 years of follow up. This extension showed that 18 years after the trial both groups have the same yearly incidence of diabetic microvascular complications, likely due to better glycemic control in the former conventional treatment group.

13.

Pearce IA, Ilango B, Sells RA, Wong D. Stabilisation of diabetic retinopathy following simultaneous pancreas and kidney transplant. Br J Ophthalmol. 2000;84(7):736–40.CrossRefPubMedPubMedCentral

14.

Shipman KE, Patel CK. The effect of combined renal and pancreatic transplantation on diabetic retinopathy. Clin Ophthalmol. 2009;3:531–5.CrossRefPubMedPubMedCentral

15.

Colucciello M. Vision loss due to macular edema induced by rosiglitazone treatment of diabetes mellitus. Arch Ophthalmol. 2005;123(9):1273–5.CrossRefPubMed

16.

Ryan EH Jr, Han DP, Ramsay RC, et al. Diabetic macular edema associated with glitazone use. Retina. 2006;26(5):562–70.CrossRefPubMed

17.

Ambrosius WT, Danis RP, Goff DC Jr, et al. Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy. Arch Ophthalmol. 2010;128(3):312–8.CrossRefPubMedPubMedCentral

18.

Navar-Boggan AM, Pencina MJ, Williams K, et al. Proportion of US adults potentially affected by the 2014 hypertension guideline. JAMA. 2014;311(14):1424–9.CrossRefPubMed

19.

Zhou MS, Schulman IH. Prevention of diabetes in hypertensive patients: results and implications from the VALUE trial. Vasc Health Risk Manag. 2009;5(1):361–8.CrossRefPubMedPubMedCentral

20.

Wang B, Wang F, Zhang Y, et al. Effects of RAS inhibitors on diabetic retinopathy: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2015;3(4):263–74.CrossRefPubMed

21.

Walraven I, Mast MR, Hoekstra T, et al. Real-world evidence of suboptimal blood pressure control in patients with type 2 diabetes. J Hypertens. 2015;33:2091–8.CrossRefPubMed

22.

Raum P, Lamparter J, Ponto KA, et al. Prevalence and cardiovascular associations of diabetic retinopathy and maculopathy: Results from the Gutenberg Health Study. PLoS One. 2015;10(6):e0127188.CrossRefPubMedPubMedCentral

23.

Wong TY, Cheung N, Tay WT, et al. Prevalence and risk factors for diabetic retinopathy: the Singapore Malay Eye Study. Ophthalmology. 2008;115(11):1869–75.CrossRefPubMed

24.

Zheng Y, Lamoureux EL, Lavanya R, et al. Prevalence and risk factors of diabetic retinopathy in migrant Indians in an urbanized society in Asia: the Singapore Indian eye study. Ophthalmology. 2012;119(10):2119–24.CrossRefPubMed

25.

Jin P, Peng J, Zou H, et al. A five-year prospective study of diabetic retinopathy progression in chinese type 2 diabetes patients with “well-controlled” blood glucose. PLoS ONE. 2015;10(4):e0123449.CrossRefPubMedPubMedCentral

26.

Doe DV, Wang X, Vedula SS, et al. Blood pressure control for diabetic retinopathy. Cochrane Database Syst Rev. 2015;1:CD006127.

27.

Armstrong C. JNC8 guidelines for the management of hypertension in adults. Am Fam Physician. 2014;90(7):503–4.PubMed

28.

Chew EY, Klein ML, Ferris FL 3rd, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol. 1996;114(9):1079–84.CrossRefPubMed

29.

•• Das R, Kerr R, Chakravarthy U, Hogg RE. Dyslipidemia and diabetic macular edema: a systematic review and meta-analysis. Ophthalmology. 2015;122:1820–7. This meta-analysis examined prospective randomized control trials to determine if there was an effect of dyslipidemia on diabetic macular edema, as suggested by some earlier cohort and case-control studies. They did not find such a link.

30.

Klein R, Sharrett AR, Klein BE, et al. The association of atherosclerosis, vascular risk factors, and retinopathy in adults with diabetes : the atherosclerosis risk in communities study. Ophthalmology. 2002;109(7):1225–34.CrossRefPubMed

31.

Nielsen SF, Nordestgaard BG. Statin use before diabetes diagnosis and risk of microvascular disease: a nationwide nested matched study. Lancet Diabetes Endocrinol. 2014;2(11):894–900.CrossRefPubMed

32.

Sen K, Misra A, Kumar A, Pandey RM. Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res Clin Pract. 2002;56(1):1–11.CrossRefPubMed

33.

Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet. 2007;370(9600):1687–97.CrossRefPubMed

34.

Talbert RL. Role of the National Cholesterol Education Program Adult treatment panel III guidelines in managing dyslipidemia. Am J Health Syst Pharm 2003;60(13 Suppl 2):S3–8; quiz S25.

35.

Nguyen NT, Magno CP, Lane KT, et al. Association of hypertension, diabetes, dyslipidemia, and metabolic syndrome with obesity: findings from the National Health and Nutrition Examination Survey, 1999 to 2004. J Am Coll Surg. 2008;207(6):928–34.CrossRefPubMed

36.

Cekic S, Cvetkovic T, Jovanovic I, et al. C-reactive protein and chitinase 3-like protein 1 as biomarkers of spatial redistribution of retinal blood vessels on digital retinal photography in patients with diabetic retinopathy. Bosn J Basic Med Sci. 2014;14(3):177–84.CrossRefPubMedPubMedCentral

37.

Klein R, Klein BE, Moss SE. Is obesity related to microvascular and macrovascular complications in diabetes? The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Arch Intern Med. 1997;157(6):650–6.CrossRefPubMed

38.

Raman R, Rani PK, Gnanamoorthy P, et al. Association of obesity with diabetic retinopathy: Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetics Study (SN-DREAMS Report no. 8). Acta Diabetol. 2010;47(3):209–15.CrossRefPubMed

39.

Lim LS, Tai ES, Mitchell P, et al. C-reactive protein, body mass index, and diabetic retinopathy. Invest Ophthalmol Vis Sci. 2010;51(9):4458–63.CrossRefPubMed

40.

Porta M, Sjoelie AK, Chaturvedi N, et al. Risk factors for progression to proliferative diabetic retinopathy in the EURODIAB Prospective Complications Study. Diabetologia. 2001;44(12):2203–9.CrossRefPubMed

41.

Dirani M, Xie J, Fenwick E, et al. Are obesity and anthropometry risk factors for diabetic retinopathy? The diabetes management project. Invest Ophthalmol Vis Sci. 2011;52(7):4416–21.CrossRefPubMed

42.

Thomas RL, Prior SL, Barry JD, et al. Does bariatric surgery adversely impact on diabetic retinopathy in persons with morbid obesity and type 2 diabetes? A pilot study. J Diabetes Complications. 2014;28(2):191–5.CrossRefPubMed

43.

Varadhan L, Humphreys T, Walker AB, et al. Bariatric surgery and diabetic retinopathy: a pilot analysis. Obes Surg. 2012;22(3):515–6.CrossRefPubMed

44.

Muni RH, Kohly RP, Lee EQ, et al. Prospective study of inflammatory biomarkers and risk of diabetic retinopathy in the diabetes control and complications trial. JAMA Ophthalmol. 2013;131(4):514–21.CrossRefPubMedPubMedCentral

45.

Foster GD, Sanders MH, Millman R, et al. Obstructive sleep apnea among obese patients with type 2 diabetes. Diabetes Care. 2009;32(6):1017–9.CrossRefPubMedPubMedCentral

46.

Dewan NA, Nieto FJ, Somers VK. Intermittent hypoxemia and OSA: implications for comorbidities. Chest. 2015;147(1):266–74.CrossRefPubMedPubMedCentral

47.

Shiba T, Sato Y, Takahashi M. Relationship between diabetic retinopathy and sleep-disordered breathing. Am J Ophthalmol. 2009;147(6):1017–21.CrossRefPubMed

48.

Rudrappa S, Warren G, Idris I. Obstructive sleep apnoea is associated with the development and progression of diabetic retinopathy, independent of conventional risk factors and novel biomarkers for diabetic retinopathy. Br J Ophthalmol. 2012;96(12):1535.CrossRefPubMed

49.

Shiba T, Takahashi M, Hori Y, et al. Relationship between sleep-disordered breathing and iris and/or angle neovascularization in proliferative diabetic retinopathy cases. Am J Ophthalmol. 2011;151(4):604–9.CrossRefPubMed

50.

Mason RH, West SD, Kiire CA, et al. High prevalence of sleep disordered breathing in patients with diabetic macular edema. Retina. 2012;32(9):1791–8.CrossRefPubMed

51.

•• Nesmith BL, Ihnen M, Schaal S. Poor responders to bevacizumab pharmacotherapy in age-related macular degeneration and in diabetic macular edema demonstrate increased risk for obstructive sleep apnea. Retina 2014;34(12):2423–30. This study found that those patients who responded poorly to anti-VEGF therapy had a higher risk of obstructive sleep apnea. This suggests that such patients should undergo screening for obstructive sleep apnea.

52.

Loprinzi PD, Brodowicz GR, Sengupta S, et al. Accelerometer-assessed physical activity and diabetic retinopathy in the United States. JAMA Ophthalmol. 2014;132(8):1017–9.CrossRefPubMed

53.

Waden J, Forsblom C, Thorn LM, et al. Physical activity and diabetes complications in patients with type 1 diabetes: the Finnish Diabetic Nephropathy (FinnDiane) Study. Diabetes Care. 2008;31(2):230–2.CrossRefPubMed

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform.

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »

Medicine Matters Diabetes

Abstract

Be confident that your patient care is up to date